Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
So far, there is no specific clinical guideline for elderly patients (>75 yr) with esophageal
squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and
randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx） or the
chemoradiotherapy group (50.4Gy/28Fx；Paclitaxel plus carboplatin). The primary end point was
3-year overall survival (OS). The second end points included life quality, radiation side
effects and 3-yr cancer specific survival.
Phase:
N/A
Details
Lead Sponsor:
Fudan University
Collaborators:
Fujian Cancer Hospital Gansu Cancer Hospital Huadong Hospital Jiangsu Cancer Institute & Hospital Ningbo No.2 Hospital Taihe Hospital The First Affiliated Hospital of Xiamen University Wuxi No. 4 People's Hospital